NASDAQ · Health care

Telomir Pharmaceuticals, Inc. (TELO)

It posted a net loss of $5.9M. At June 30, 2026 it held $5.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

What Telomir Pharmaceuticals, Inc. does

Telomir Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TELO.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	n/a	-$10.4M	-$0.33	n/a
2024	n/a	n/a	-$16.5M	-$0.56	n/a
2023	n/a	n/a	-$13.1M	$0.48	n/a
2023	n/a	n/a	-$854.1K	-$0.03	n/a

Latest SEC filings

What Telomir Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 17, 2026
Investor disclosure 8-K
September 16, 2026
Shareholder vote results 8-K
September 14, 2026
Investor disclosure 8-K
August 19, 2026
Additional proxy material DEFA14A
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026
August 10, 2026
Investor disclosure 8-K
July 28, 2026
Proxy statement DEF 14A
June 15, 2026
Investor disclosure 8-K
June 8, 2026
Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 27, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about TELO

What does Telomir Pharmaceuticals, Inc. do?

Telomir Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TELO.

Is Telomir Pharmaceuticals, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $5.9M.

When did Telomir Pharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 17, 2026.

Similar companies

Follow TELO

Get an email when Telomir Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TELO: get an email when it files

Where the numbers come from

Financial figures are the values Telomir Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.